Medication info
Dikyuban Tablet 40 mg (Valsartan)

Dikyuban Tablet 40 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›40mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500724 · Approved 2025.03.27 · Insurance code 650206140

Summary

Main use
Treatment of essential hypertension and heart failure, reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be used concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with 40 mg once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily; it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily, followed over several weeks by dose increases, depending on the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure, reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction.
View approved original text

This medication is used to control blood pressure in patients with essential hypertension. It is also prescribed to ease symptoms and improve heart function in patients with heart failure who are intolerant to ACE inhibitors. Additionally, it helps to reduce the risk of death in patients with impaired left ventricular function after myocardial infarction. In summary, this medication is effective for essential hypertension, heart failure (especially in patients intolerant to ACE inhibitors), and reducing the risk of death after myocardial infarction. Therefore, it is used to improve cardiovascular health.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be used concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with 40 mg once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily; it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily, followed over several weeks by dose increases, depending on the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or more. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. It should not be used by individuals who are allergic to this drug or its components, pregnant or breastfeeding women, and those with severe liver or kidney dysfunction. Patients with liver cirrhosis or biliary excretion disorders are also advised to avoid this medication. Patients with a history of angioedema or those who have experienced angioedema should avoid this medication. Diabetic patients with moderate to severe renal impairment should be cautious not to combine this medication with certain drugs. Elderly patients or those with high blood potassium levels, and patients with mild to moderate liver impairment should have their doses adjusted and be monitored closely when using this medication. Patients with heart valve disease or hypertrophic cardiomyopathy, and those with ischemic heart disease or cerebral vascular disease should be careful to avoid excessive drops in blood pressure. When first taking this medication, blood pressure may drop rapidly, causing dizziness or fainting, so particularly those with low fluid or sodium levels should start at a low dose and gradually increase. Patients with renal artery stenosis may experience renal function deterioration, so renal function should be monitored closely while taking this medication. Patients with heart failure or after myocardial infarction may experience changes in kidney function, so regular kidney function tests are important. This medication lowers blood pressure, so caution is advised while driving or operating machinery as dizziness or drowsiness may occur. Taking this medication with potassium-sparing diuretics or potassium supplements may lead to dangerously high potassium levels, so consultation with a physician is necessary when taking together. When taken with non-steroidal anti-inflammatory drugs (NSAIDs), the blood pressure-lowering effect may be reduced and renal function may deteriorate, so caution is advised. Taking it with lithium preparations may increase lithium levels and result in toxicity, so monitoring of blood lithium levels is needed. In case of overdose, blood pressure may drop very low, requiring immediate medical attention for appropriate treatment. This medication has not been established for safety and efficacy in children and adolescents, thus its use is not recommended. When stored, keep it out of reach of children and do not transfer it to another container.

Side effects

  • headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 48 more
  • stomach ache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal function impairment
  • hyperkalemia
  • angioedema
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • bullous dermatitis
  • reduced red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • increased BUN
  • dyspepsia
  • anemia
  • tinnitus
  • anxiety
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia
  • drowsiness
  • vomiting
  • constipation
  • thirst
  • appetite loss
  • malaise

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. It is also important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.